A Pharmacodynamic Study of Pre-prostatectomy BKM120 in Men With High-risk, Localized Prostate Cancer

Trial Profile

A Pharmacodynamic Study of Pre-prostatectomy BKM120 in Men With High-risk, Localized Prostate Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Buparlisib (Primary)
  • Indications Prostate cancer
  • Focus Biomarker; Pharmacodynamics
  • Sponsors Novartis
  • Most Recent Events

    • 17 Jul 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 10 Jun 2017 Biomarkers information updated
    • 07 Jun 2016 Results (n=11) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top